GlaxoSmithKline Pharmaceuticals: The financial results for the period ended September 30, 2026
GlaxoSmithKline Pharmaceuticals (GLAXO) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹42,883 crore.
What happened
GlaxoSmithKline Pharmaceuticals (GLAXO) filed a disclosure with the exchanges on 3 November 2026 at 06:49 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
GlaxoSmithKline Pharmaceuticals is a mid-cap company in the Healthcare sector, with a market value of about ₹42,883 crore.
The stock last traded at ₹2,531.4, against a 52-week range of ₹2,088.1–₹3,120.7 (18.9% below the high).
Before this filing the shares had moved −8.6% over the month and −4.9% over three months. Average daily turnover over the last 20 sessions was about ₹11.78 crore.
Promoters held 75.00% at the end of Q1 FY27. Foreign institutions owned 4.79% and domestic institutions 7.80%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 805 | 205 | 12.1 |
| Q2 FY26 | 980 | 257.5 | 15.07 |
| Q3 FY26 | 1,041 | 295.6 | 16.54 |
| Q4 FY26 | 995 | 277.9 | 16.4 |
| Q1 FY27 | 938 | 237.2 | 14 |
What history shows
This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.
Across 300 similar disclosures by other Healthcare companies, shares moved +1.4% on average the next day and +1.9% over five days; 57% of them rose the next day.
Market-wide, 10,321 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 3 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.